

Microbiome Resilience after Infection

Wotsomu Evasi

Clinical Pharmacology and Antimicrobial resistance Kampala International University Uganda
Email: evasi.wotsomu@stdwc.kiu.ac.ug

ABSTRACT

The microbiome is a complex and dynamic ecosystem that contributes to host metabolism, immunity, and disease resistance. Infections represent major perturbations to this system, often disrupting microbial composition, diversity, and function. The resilience of the microbiome, its capacity to recover equilibrium after disturbance, is critical for restoring health and preventing long-term complications. Mechanisms of disruption include pathogen-induced inflammation, epithelial barrier damage, and secondary effects of antibiotics, leading to loss of colonization resistance and dysbiosis. Factors influencing resilience include host genetics, diet, environmental exposures, and the presence of microbial reservoirs. Recovery follows reproducible phases of succession, from initial restoration of diversity to the re-establishment of functional pathways. Case studies of bacterial, viral, and fungal infections illustrate variability in resilience, highlighting the importance of community context and infection severity. Emerging biomarkers, multi-omics approaches, and computational models are improving the measurement of resilience, while therapeutic strategies including dietary interventions, probiotics, fecal microbiota transplantation, and microbiome-informed drug development hold promise for enhancing recovery. Ethical and privacy considerations remain central as microbiome science advances. Understanding and promoting microbiome resilience after infection has profound implications for clinical practice, public health, and precision medicine.

Keywords: Microbiome resilience, Infection recovery, Dysbiosis, Fecal microbiota transplantation, and Precision medicine.

INTRODUCTION

The microbiome constitutes the complex community of microorganisms residing within an organ or other compartments of the body [1]. Characterized by its remarkable degree of diversity, ranging from four different kingdoms of life and thousands of species within each [2], a great number of which remain now yet characterized, it clearly represents one of the most complex systems underlying health. Bacterial, viral, fungal, and archaeal populations cooperate to sustain pivotal metabolic and immune functions across the entire life span. By resisting infection, the microbiome can be defined as resilient, meaning the ability of a system to recover equilibrium after disturbance [2].

Understanding the Microbiome

The composition of the microbiome encompasses all microorganisms inhabiting an environment; in the human body, it is dominated by bacteria, which typically comprise 1 to 3% of body mass in healthy adults and exhibit large interpersonal variation [2]. Microbial community assembly results from dispersal, diversification, environmental selection, and ecological interactions [2]. Considering the extensive metabolic capabilities coded in microbial genomes and the diversity and density of the microbiota, the collective metabolic potential of the community significantly exceeds that of the host. Microbial species residing in the human body encode more than eight million proteins, while the human genome contains approximately 20,000 protein-coding genes [3].

Composition of the Microbiome

The human microbiome is a complex ecosystem encompassing bacteria, viruses, fungi, and other microbes found on and within the body [4]. The microbiome consists of a contiguous community spanning the upper and lower airways and the gastrointestinal tract; these microbial ecosystems are spatially organized and pivotal in preserving

bodily health in steady-state conditions [4]. The gastrointestinal assemblage typically includes Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria, whereas the lungs predominantly harbor Firmicutes and Proteobacteria. The composition of the microbiome varies among distinct body sites. For instance, the skin is rich in Actinobacteria and Actinobacteria, dental plaques and saliva favor Bacteroidetes, Proteobacteria, and Actinobacteria, and the vaginal environment predominantly contains Lactobacillus spp. and Actinobacteria [4].

Functions of the Microbiome

The human gut is known to harbor a large number of microbes that provide important functions, including competitive inhibition of ingested pathogens [5]. Several functions can be attributed to the gut microbial community to include food metabolism via bacterial enzymes that help break down otherwise indigestible components; synthesis of essential vitamins, such as B12 and vitamin K; stimulation of angiogenesis and intestinal tissue differentiation; toxin degradation and host toxic compound metabolism and absorption; and, important for this study, resistance to pathogen colonization [6]. Other reported functions of the microbiome include the influence on the activation and efficiency of the immune system and the maintenance of structures that limit the contact of the immune system with the gut microbiome.

Impact of Infections on the Microbiome

Infections can disrupt essential microbial taxa or alter community structure, impairing the microbiome's ability to carry out vital functions [3]. Examples range from acute infection by antibiotic-resistant pathogens to chronic infection by Mycobacterium tuberculosis in the lung, Giardia in the gut, and Leishmania in the skin. Resilience requires the ability to suppress and outcompete the invading pathogen [2]. Mechanisms include depletion of nutrients necessary for pathogen growth and production of antimicrobial molecules that eliminate the pathogen. Recovery of the commensal microbiota will restore these functions; conversely, failure to recover will prolong infection and delay healing [7]. Disruption can also provide an opportunity for immunopathology and disease through the release of inflammatory agonists or greater susceptibility to subsequent infectious or non-communicable disease.

Types of Infections Affecting the Microbiome

Infections exert a strong influence on the tissue-associated and fecal microbial communities [8], thereby affecting the microbiome's resilience throughout the recovery process. The infecting agent may be bacterial, viral, parasitic, or fungal in nature, and prevalence can vary widely across hosts and recovery periods. Certain infections, notably the enteric bacterium Clostridium difficile, are associated with specifically high rates of microbiome disturbance due to their outsize effects on microbial metabolism and composition. The appearance and severity of microbiome disruption depend both on the community composition at the start of infection and on extrinsic factors such as the pathogen species and abundance. For instance, Salmonella enterica infection triggers pronounced shifts in community composition and heightened release of markers indicative of gut inflammation [9]. When infection coincides with prior antibiotic administration, the resulting disruption may be even more severe. Bacterial and viral infections can induce excessive localized inflammation, which compromises the epithelial barrier and damages mucosal tissue; such physical perturbations disturb tightly associated microbial communities, often resulting in long-term elevation of enteric Proteobacteria. Compounding these effects, antibiotic administration may leave niches accessible to secondary colonization by opportunistic pathogens [10].

Mechanisms of Microbiome Disruption

Infection, especially when acute and localized at specific tissue sites such as the respiratory and gastrointestinal tracts, can alter the resilience of the microbiota, shifting both bacterial composition and function through diverse mechanisms [11]. Microbiota-mediated colonization resistance represents an organism's first line of defense against pathogenic invasion. Host-associated microbial communities engage multiple mechanisms, including the production of inhibitory molecules and antibiotic scavenging, direct competition for crucial nutrients, and the stimulation of protective host immune responses. Successful competitive bacteria elicit a concerted multilayered defense that blocks pathogen colonization and prevents disease [5]. While the microbiota benefit the host by constraining pathogen colonization, invading pathogens antagonize the microbiota in a bid to claim previously occupied niches or create environments that favor their own establishment and expansion. Infection-induced inflammation initiates a long series of contesting microbiota–pathogen interactions within the intestinal ecosystem. Microbiota members employ a diversity of strategies to tolerate host- and pathogen-mediated perturbations: Bacteroidetes modify their lipopolysaccharide structure to increase resistance to host antimicrobial peptides, while some Proteobacteria survive iron depletion by utilizing siderophores produced by other species [5].

Factors Influencing Microbiome Resilience

The factors influencing host-microbiome resilience after infection reflect the complex interplay between a microbial community, the phagocyte that regulates it, and its habitat. In many ways, this is reminiscent of parasite

transmission, where three components: a parasite, a host, and the environment determine whether or how transmission will occur [3]. Similarly, a microbial community, its environment, and an infected host jointly determine the outcome of recruitment and persistence under the additional constraint of containment by phagocytic cells that continuously monitor population size. Of these, the environment, specifically, the pool from which the microbiome is recruited to play a pivotal role in deciding which species can be part of the postinfection microbiome and whether or not the replacement metacommunity will have the resilience to evolve into a persistent beneficial assemblage [3]. Consistent with a critical role for environmental reservoirs, several studies illustrate an enhanced propensity for microbiome recovery in the presence of a guild of critical taxa that constitute an environmental reservoir of microbial diversity, facilitating successful assemblage after disturbance [12], and the gut microbiome of nursing infants is more resilient than that of adults. Host genetics, diet, and environmental factors also contribute importantly to microbiome resilience, where recovery is favored by a resilient, biodiverse replacement community located in an appropriate filter or environmental habitat [3, 12].

Host Genetics

Host genetic variation exerts a pervasive impact on the composition and function of indigenous microbial communities across diverse human body sites. Genome-wide association studies reveal significant links between host genotype and the relative abundance of specific taxa, implicating immunity-related pathways in mediating such control. In the mammalian gut, polymorphisms in innate immune genes such as NOD2 profoundly influence microbial community structure, contributing to inflammatory bowel disease (IBD) susceptibility. Coordinated analyses of host genotypes alongside microbiome data across multiple large cohorts identify numerous immunity-linked genomic regions that associate reproducibly with microbiome composition; several of these colocalize precisely with known IBD risk loci and highlight complex interactions between host genetic pathways and the microbiota [13]. Human genetics, therefore, constitutes a critical factor controlling parameters of microbial community composition at body sites commonly colonized by microorganisms [13, 14]. Numerous studies in humans, mice, and other animals reveal that complex traits are generally polygenic and influenced by both environmental and host genetic factors; gut microbial communities appear to follow the same general pattern. Host genetic impact on the microbiome is species-specific and body-site specific, with particularly strong effects observed within the gut. At this body site, specific human genetic variants in several genes including NOD2, a key sensor of bacterial peptidoglycan, have been associated with notable shifts in the enteric microbiota [14].

Dietary Influences

Dietary intake significantly modulates the composition of the microbiota and affects its resilience. Shifts in microbial assemblage and function can alter the risk of pathogen or opportunistic microbe overgrowth during infection [15]. Early work found that mice subjected to a Western-style diet exhibit a dramatic change in colonisation resistance and clearance of the pathogen *Citrobacter rodentium* [16]. Loss of microbiota density and diversity caused by such a diet manifests as a diminished capacity of the microbiota to prevent pathogen colonisation through resource competition and to stimulate efficient anti-microbial immune defence. As noted elsewhere, the connection between diet and the microbiota is a longstanding and dynamic field of microbiology, while relatively few studies have explicitly studied the role of diet on microbiome resilience. However, the combined evidence also suggests that optimal nutrition provides a fundamental platform for microbiome recovery [15, 16].

Environmental Factors

Environmental factors significantly influence microbiome recovery following infection, as properties of the microbial environment shape microbiome responses to disturbance [17]. Habitats differ in spatial and temporal heterogeneity; microbial species pool sizes, connectivity, and resource availability, thereby affecting community assembly and responses to disruption. Animal gut microbiomes exhibit low diversity and limited dispersal due to host physiology, which constrains recovery potential. Soil microbiomes are characterized by high diversity yet poor connectivity, further modifying recolonization patterns [17]. In environments lacking host-mediated selection and containing high diversity, post-disturbance taxonomic communities often diverge from their initial configuration. The meta-community framework facilitates comparisons of microbial responses by analyzing sequencing data to quantify bacterial richness and compositional shifts. Across ecosystems, disturbance generally leads to reductions in community richness; however, specific environmental changes, such as the addition of sewage sludge, can increase richness [17].

Microbiome Recovery Post-Infection

The microbiome's return toward homeostasis following infection encompasses multiple phases [7]. The initial phase occurs near the offset of clinical symptoms and generally involves the restoration of community-wide diversity alongside broad functional diversification [18]. A transitional phase follows, characterized by the re-establishment of individual taxa to near pre-infection abundance levels, the return of strain-level diversity within

many lineages, and an increase in the average ribosomal RNA (rRNA) operon copy number indicating a shift toward bacteria with faster growth rates. Completion of recovery is marked by the reappearance of the majority of pre-infection taxa, strains, and gut metabolic modules, with the community suitably prepared for future perturbations [7]. During recovery, probiotics can be beneficial, conferring advantages such as suppression of pathobionts and provision of health-promoting metabolic pathways [18].

Stages of Recovery

Infections may reduce the diversity of the gut microbiota or cause blooms of specific taxa [18]. Along with the cessation of diarrhea, the community undergoes a reproducible series of succession events, termed the 'Early', 'Mid', and 'Late' phases. In the Early phase, facultative anaerobes of the family Enterobacteriaceae and streptococci proliferate; these oxygen-tolerant taxa probably aid the return of obligate anaerobes by reducing oxygen tension in the gut. Species that increase in the mid phase include Bacteroides spp. and members of the Lachnospiraceae and Ruminococcaceae; these have high representation genes that scavenge oxygen and reactive oxygen species. Late stage microbiotas are similar to the pre-infection state [18]. Supplementing the diet of infected adults with the carbohydrate rice starch during the mid-phase promoted the growth of Ruminococcaceae and accelerated recovery. Bursts of taxon-specific noise can drive switches between alternative stable states of the intestinal microbiota [2]. Recovery following antibiotics is therefore sensitive to the abundance of community members at the end of treatment, their intrinsic ability to withstand subsequent stresses, and the capacity of their populations to grow fast before others take over.

Role of Probiotics in Recovery

The recovery of the intestinal microbiome after an infection usually includes several stages and depends on several factors [19]. The return to a healthy microbiome composition generally occurs in the following order: (i) recovery of bacterial numbers and concentrations (at species and strain levels), (ii) recovery of bacterial diversity and recruitment of species, (iii) secondary metabolites and biochemical pathways, and (iv) full recovery of bacterial activities, gene expression, and restoration of trophic interactions. Supplementation of defined bacterial species, such as probiotics or faecal transplantation, can enhance recovery [4].

Case Studies on Microbiome Resilience

The dynamic balance of the gut microbiota can be severely disrupted by pathogen colonization, often resulting in antibiotic treatment that reduces the native microbial community. The disruption persists thereafter, and microbiota-mediated functions remain impaired, thus compromising the host's health. The ability of a microbiome to return to its original state after an infection, or to recover its functional capacity despite compositional changes, is referred to as resilience [3]. The microbiome's resilience depends on its adaptation to host-specific and environmental factors, which dictate the post-infection reconstruction trajectory and determine the associated risk for infections and immune-related diseases. The efforts to assess resiliency in the microbiome and other microbial communities can contribute to designing personalized therapy, and the analysis of microbiome-relevant ecosystems is indicative of the microbiome's capacity to recover after infection [3]. Several examples illustrate distinct microbiome-resilience behaviors. A patient experiencing acute pancreatitis illustrates bacterial-reseeding dynamics despite microbial-community contraction [20]. The microbiota decreased by two orders of magnitude during intensive care, and Enterococcus species became dominant, seemingly transmitted between the skin, biliary duct, and gut and exhibiting a high degree of antibiotic resistance. However, the diversity and metabolic potential of the gut microbiota fully recovered upon discharge. Enterococci maintained their dominance during extensive antibiotic treatment, and colonization resistance towards Enterococcus was therefore low in this individual. Enterococcal dominance thus signaled a microbiome-specific risk for multi-drug-resistant-enterococci (MDRE) infection [3]. In vivo experiments of influenza virus or Candida albicans infection have also demonstrated variable recovery behavior, particularly in the relative abundance of dominant species. Resilience after either less severe or non-gastrointestinal infections is often less impacted than after severe infections and can reconstruct significant fractions of the original microbial community. Influenza infections confer lower damage, and damaged bacteria appear to be exchanged with the respiratory microbiota, which selectively seeds particular species. Candida infections involve fungal invasion of the mucosa, similar to bacteria, and therefore exert more comparable effects to bacterial infections. A healthy, balanced-response microbiome can facilitate desired outcomes by suppressing potential pathogens and stimulating the mucosal immune system to achieve homeostasis. Disease severity and the portal of entry are thus major factors influencing resilience, and the outcome is highly dependent on the specific microbiome configuration [3].

Case Study 1: Bacterial Infections

The overall effect of the infection on the gut microbiome, measured by the inverse Simpson index at species-level operational taxonomic unit (OTU) resolution, was 0.1 and was classified as a bacterial infection [21]. This classification system enables a retrospective discrimination of microbiome resilience. A gut microbial ecosystem

undergoing an imbalance due to an infection and subsequently recovering exhibits resilience. However, the return to the initial state is not guaranteed, especially within the typical sampling timeframe of 96 hours, indicating that the host's capacity to re-establish its luminal microbiota is insufficient during this period. If the ecosystem transitions to an alternate stable state different from the initial condition, as can occur following a bacterial infection, the microbiome's resilience can be considered as completely lost [21].

Case Study 2: Viral Infections

The human gut microbiota exhibits variable resilience to enteric infections, with some microbial communities fully recovering post-challenge and others showing lasting shifts. A human challenge study with Norovirus found that a subset of individuals remained asymptomatic despite infection [22]. These asymptomatic microbiomes had a significantly greater abundance of Bacteroidetes, especially Bacteroidia, a profile associated with healthier gut communities and recovery from enteric bacterial infections. This suggests that elevated Bacteroidetes may facilitate resistance to or neutralization of viral pathogenicity [22]. Similarly, murine experiments demonstrate that bacterial and viral communities can respond independently to dietary disturbances, with Caudovirales bacteriophages, correlated with taxa such as Bacilli, Erysipelotrichales, and Clostridiales, playing a role in microbial dynamics. The virome's temperate lifestyle and history of dietary exposure influence its functional profile and indicate that viral and bacterial assemblages can develop autonomously, affecting resilience to perturbations. These insights highlight the complexity of virus-bacteria interactions governing community stability during environmental shifts [23].

Case Study 3: Fungal Infections

Gut mycobiome dysbiosis is prevalent in patients with critical illnesses and is believed to increase susceptibility to fungal infection in the bloodstream. Existing data on fungal alteration following critical injury remains scarce. A murine model of cecal ligation and puncture or pseudomonal pneumonia was used to investigate the impact of sepsis or trauma on gut fungal communities [24]. Terminal-fecal samples were collected after 48 h, and 16S-rRNA/ITS-amplicon sequencing was performed. The gut mycobiota of human survivors of sepsis/trauma was also interrogated from stool samples collected 2 weeks after intensive care unit admission. Both models exhibited gut bacterial dysbiosis early after injury. Cecal ligation and puncture or pseudomonal pneumonia caused an increase in gastric *Candida* spp. and stool fungal diversity but a decrease in stool fungal biomass and *Malassezia* spp. Similarly, plasma β -glucan was increased in survivors [24]. In the patient population, fungal diversity and biomass exhibited strong inverse correlations with the severity of the initial organ dysfunction and the kinetics of severe organ dysfunction resolution. Microbiome decontamination of the gut had a minimal effect on fungal burden after injury despite a reduction in overall β -glucan levels [24]. In vitro, fecal samples from individuals with critical illnesses promoted the growth of *C. albicans* from stomach to colon through an interaction with both bacteria and nutritional environment. Cecectomy neutralized the elevation in gastric *Candida* spp. observed after injury, followed by a loss of the observed altered growth kinetics. These findings indicate persistent fungal dysbiosis in circulation and stool after critical illness that approaches two weeks despite the resolution of other pathophysiological disruptions, implying a potential role in post-critical illness morbidity and mortality. Fungal resilience for the first two weeks following sepsis or trauma in circulating plasma, stomach, ileum and stool was demonstrated [24].

Measuring Microbiome Resilience

High-throughput sequencing and metabolomics techniques, in combination with hierarchical statistical modeling, reveal patterns of linked variation in both composition and function that distinguish resilient from non-resilient individuals over time [1]. Capturing resilience requires incorporating temporal structure in the data. Mathematically, resilience indicates a return to equilibrium after a perturbation; thus, a one-time snapshot cannot, by definition, measure it [25]. Equilibrium models accommodate both steady-state and cyclic data, reflecting the inherent natural fluctuations of an intact microbiome. Although information-theoretic quantification of resilience is a promising avenue, a comprehensive toolbox of analytic methods remains to be fully developed [1, 25].

Techniques for Microbiome Analysis

The human microbiome is a complex microbial ecosystem that exists in a delicate state of homeostasis. Normally it exhibits resilience, its ability to productively recover towards the original stable state. An infection that directly disturbs the microbiome is a stress to the microbial ecosystem and tests this resilience. A multitude of techniques are available to investigate the changes that take place in the microbiome during and after infections. Microbiome study begins with sampling of the microbial species that colonize specific places of the human body [1]. The collected samples are then subjected to various pretreatment methods. Subsequently, the samples proceed to nucleic acid analysis, metabolite analysis, and protein analysis. The high-throughput generated data are eventually analyzed by bioinformatics tools [1, 25]. Sample-based analyses constitute a crucial initial process of microbiome

study, and these can be broadly categorized into sampling, pretreatment, and nucleic acid processing. Sampling consists of steps aimed at the isolation of microbes from specific body parts of individuals for subsequent examination. These microbes can then be exposed to metagenomic, metatranscriptomic, or metaproteomic analysis [1]. Regardless of the determination technique employed, the samples must undergo appropriate pretreatment steps prior to further processing. For DNA or RNA probes, the pretreatment generally involves nucleic acid extraction, concentration, and purification, each requiring dedicated kits or reagents. Microbiome community DNA/RNA isolation kits facilitate nucleic acid extraction, the removal of PCR inhibitors commonly found in samples, and nucleic acid purification. After pretreatment, the nucleic acid probes are prepared using appropriate sequencing library preparation kits to ensure compatibility with the sequencing platform [25].

Biomarkers of Resilience

Resilience, the ability of a system to return to its original state after undergoing stresses due to perturbations, is a beneficial strategy for maintaining optimal health in the context of microbiomes. Characterizing microbiome resilience poses a fundamental challenge, as a universal measure of resilience remains elusive. The gut microbial composition in swine, enriched by host-genome information, stands as an ideal model to investigate the intricacies defining microbiota resilience in the wake of infections [1]. A comprehensive analytical framework was developed to characterize the resilience of 204 piglets following an enterotoxigenic *Escherichia coli* (ETEC) infection, drawing upon four different classes of statistical indicators and four resilience definitions. Findings delineated two indicators of resilience that proved efficient in capturing the resilience phenomenon. Analysis uncovered a robust association between microbial composition and resilience with regards to both composition and richness. Less-resilient animals exhibited decreased α -diversity, while specific amplicon sequence variants along with KEGG pathways tied to inflammatory responses showed a negative correlation with resilience. When resilience indicators were aggregated into classes, significant microbial composition differences emerged predominantly among the less-resilient subjects [1]. Collectively, microbial components of the gut emerge as potential biomarkers for distinguishing individuals exhibiting lower resilience. These insights hold pivotal implications for both the foundational understanding of microbiome resilience and the formulation of interventions aiming to enhance microbiota resilience following infections [1].

Therapeutic Approaches to Enhance Resilience

Microbial dysbiosis following infection can result in persistent inflammation and host immune dysregulation, contributing to chronic disease or increased susceptibility to secondary infections [4]. Bacterial and viral infection, broad-spectrum antibiotics, chemotherapy, radiation therapy, toxic compounds, aging, diet, lifestyle, and stress are among the personal and environmental stressors disrupting colonization resistance and damaging the indigenous microbiota [4].

Dietary Interventions

As resilience is an important attribute of a system challenged with a perturbation, dietary shifts represent one means to promote microbiota resilience. The microbiota and host benefit from the usual mix of nutrients, including carbohydrates, proteins, and fats. Upon perturbation, however, the host often benefits from preferential use of particular macronutrients. Increased protein intake supports carbohydrate fermentation [26], whereas dietary fiber maintains a healthy core colonic microbiome, community diversity, and bacterial load, all of which support more rapid microbiota recovery [27]. Brief periods (<1 week) of dietary restriction alter the colonic microbiota and compromise host health, even as the health benefits of enduring reductions in calorie intake remain under study, at least in rodents [28]. Finally, fasting stresses the microbiota directly and promotes a shift to a community dominated by mucinophiles, which likely provides alternative sources of nutrients under such adverse conditions [28].

Fecal Microbiota Transplantation

Fecal microbiota transplantation encompasses the administration of fecal suspension from a healthy donor into the intestinal tract of a patient. Consequently, fecal microbiota transplantation can be viewed as an attempt to restore microbiome resilience following an imbalance resulting from infection [27]. Both invasive and noninvasive delivery pathways have been developed in practice. The microbiota originating from various locations in the donor are contained in the suspension and can be transferred into corresponding locations in the recipients. For example, a suspension derived from the donor's colon can be administered either through the upper gastrointestinal route (e.g., oral or nasogastric) or via lower routes such as colonoscopy or enema [28]. Numerous randomized controlled trials have confirmed that fecal microbiota transplantation achieves remarkable clinical efficacy when performed on patients suffering from recurrent *Clostridium difficile* infection. The rationale for this therapeutic strategy is the restoration of the gut microbiota, which, in turn, elevates colonization resistance and inhibits the growth and reproduction of *Clostridium difficile* in the colon. Furthermore, fecal microbiota transplantation

effectively cures recurrent extraintestinal infections caused by multidrug-resistant bacteria or fungi through reconstruction of the recipient's colonization resistance. This approach has also proved valuable in enhancing the resilience of the gut microbiota against bacterial infections following antibiotic administration [29].

Pharmaceuticals and Microbiome Modulation

Drugs including antibiotics, antivirals, and antifungals, profoundly influence the host microbiota [29]. Antibiotics affect microbial composition, diversity, and load, with disruptions commonly altering taxa associated with resistance mechanisms [29]. This is illustrated where treatment with the β -lactam antibiotic cefprozil increases the abundance of resistance genes (e.g., β -lactamases) in both recovered and unrecovered microbiomes. Antiviral therapy influences beneficial commensals, although the impact depends on the virus and treatment used. Antifungal drugs have recently been shown to alter microbial composition by increasing the relative abundance of opportunistic pathogens in the setting of fungal infection. Biologics inhibit various inflammatory cytokines to correct dysregulated immunity, restoring autoimmune balance. The initiation of novel peptide therapeutics and biological agents will likely reduce the usage of conventional pharmaceuticals, yet impact microbiota-based resilience with both potentially harmful and beneficial consequences, thus microbiome research–drug interactions remains of critical importance [29].

Future Directions in Microbiome Research

Emerging technologies such as metatranscriptomics and metaproteomics provide new avenues to measure microbiome resilience, enabling detailed monitoring of functional recovery and community interactions post-infection [28]. Longitudinal studies are critical to characterize the timing, extent, and long-term outcomes of resilience, identifying factors that promote or hinder restoration across diverse clinical contexts [28, 29].

Emerging Technologies

The advancement of molecular technologies such as single-cell genomics and spatial transcriptomics promises unprecedented structural and functional resolution in microbiome studies. These technologies enable the dissection of microbiome diversity and heterogeneity at the cellular level, providing the potential to interrogate unambiguously the mechanisms associated with microbiome resilience [30]. Applying these techniques to dissect the interplay between the microbiome and the host will generate new knowledge and open avenues for both preventative and therapeutic interventions [30].

Longitudinal Studies

Longitudinal studies of the microbiota enable the discovery of community alterations that fundamentally affect a host's ability to maintain health. Employing a murine model of infectious colitis (*Citrobacter rodentium*), a 2-month time-series of fecal microbiota profiles resolves dynamic alterations in microbial communities at multiple levels of granularity [31]. A suite of computational methods extracts time-varying signatures for individual taxa and microbial sub-communities and links microbial dynamics to physiological changes documented through the course of infection [31]. The analysis identifies signatures implicating small subsets of taxa as key elements in host responses during distinct stages of colitis, highlighting two transitions in the pathogenesis: an early disruption of the colonic mucus layer following pathogen colonization and a subsequent increase in abundances of Clostridiales and Lactobacillales during inflammation resolution. Quantitative culture data corroborate the signatures and provide additional context for interpreting microbial behaviours within host ecosystems, informing studies of resilience and promoting the development of integrative approaches to microbiome data analysis and to pathology [31].

Ethical Considerations in Microbiome Research

Informed consent is a prerequisite for conducting responsible medical and scientific research involving human participants. Microbiome science complicates this process to an unprecedented degree. Besides the individual, some of the principle biological research objects include a highly dynamic microbial community and its composite metagenomes, various forms of residual clinical and environmental specimens, and associated demographic, socio-economic, and clinical data [32]. Direct involvement of human populations in this research requires special attention to procedures for obtaining, interpreting, and negotiating informed consent. Study designs incorporate numerous confounding elements that require emphasis during informed consent negotiations, including vulnerability, stigmatisation, scientific and statistical illiteracy, and disease aetiology [32]. Stewardship stewardship, particularly with respect to the collected microbiota and metagenomic data, represents another major concern. When data are assembled and maintained on open-access databases, the potential exist for exploitation and use in non-medical applications such as forensic identification. Concerns regarding biobanking, ownership, and benefits extend beyond stewardship and relate to the proper management of sensitive health and non-reference microbiome data collected over time from vulnerable and stigmatised populations [32]. Special situations, such as violent crimes, immigration, and border control, require clear policies that guarantee protection of the

participants' interests and confidentiality. Particular attention should be paid to the still-developing infrastructure of the rapidly evolving field and chain of custody. It remains to be seen whether current and projected regulations are adequate and sufficient [32].

Informed Consent

Participation in the research outlined in this proposal is completely voluntary. Individuals are free to decline participation or to withdraw at any time, for any reason, with no penalty or loss of benefits to which they are otherwise entitled. Withdrawal from the study will not affect current or future relations with the investigators or the university. Choosing not to participate will not result in any loss of benefits to which the participant is otherwise entitled [32]. Written consent to participate in the study will be obtained during an in-person recruitment visit. During this visit, a detailed explanation of the consideration to participate in the study will be provided; the opportunity to ask questions will be offered, and a copy of the consent page will be left with the participant. Participation will not be allowed without a signed consent form, and only participants who sign the consent form will be enrolled. If an individual consents to participate, the consent form will be signed and dated by both the participant and the Principal Investigator (PI). The participant will receive one copy of the signed consent form. Subjects may print out the consent form before signing for their records [32]. The form will be retained.

Data Privacy Issues

Informed consent is fundamental to the ethical conduct of human subjects' research, with guidelines delineating its application in microbiome studies [32]. Crucial components include a clear description of the research, disclosure of associated risks, confidentiality assurances, and identification of potential benefits. However, researchers must navigate unique challenges that impact participant understanding and result in emergent ethical considerations and participant expectations [32]. Data privacy is a particularly acute concern within microbiome research. Notwithstanding common perceptions, human microbiome data is not exempt from privacy issues; its uniqueness parallels that of an individual's DNA, which underpins forensic and biomedical profiling. Analysis of human microbiome data, especially when linked with personal information, could yield insights into health, predispositions, and behavior. Emerging studies suggest that such analyses can enable re-identification of participants, highlighting the limitations of removal of personal identifiers. Full anonymization may be both undesirable, as data remain linked to samples, and unfeasible, whereas the imposition of strict data access controls could constrain research efforts [32]. Questions of ownership, rights, and control of human microbiome data are not clearly articulated for researchers, participants, or funding agencies. Access to databases relies on publication records, yet non-disclosure agreements and data-sharing restrictions are prevalent. Responsibility for data management and oversight, or for whistleblowing in the case of data abuse or misuse, remains ill-defined. Distribution of benefits, both monetary and nonmonetary, among stakeholders is consequently uncertain. Hosting providers of microbiome data consequently face competing interests and increased risks, compounded by unclear ownership rights. Challenges also extend to the management of associated biospecimens, which require protection from loss, contamination, or mislabeling, complications exacerbated by the potential for individuals to claim ownership and invoke property rights [31, 32].

Public Health Implications

Microbial communities instruct host health and disease, inspiring public-health interventions that nourish beneficial microbiome functions [33]. For example, oral health problems in disadvantaged children under public care may be addressed by promoting beneficial biofilm assembly by fish consumption. Probiotics can protect from infection and antifungal treatments counter viral inflammation [34]. Microbiome screening could help prioritise antibiotic treatment for high-risk individuals, but implementation is challenging. The loss in microbial diversity from infection justifies new monitoring programmes in closed atmospheric systems like hospitals, offices or aircrafts that offer access to vulnerable individuals. Incorporating bioinfrastructural elements like microbial green space improves physiological and psychological health by inducing resilient microbiome states. Microbiome harmonisation should militate against selection pressures that favour highly transmissible variants that increase the incidence of long Covid and related pathologies [33, 34, 35].

Microbiome and Disease Prevention

The microbiome consists of innate and acquired environmental exposures from premises, carers, co-habitees, and pets that continually shape an individual's microbiota. Broadly, the development of a resilient microbiome represents a balanced host-microbe environment that restores a stable ecosystem after an acute challenge or perturbation such as antibiotics or diarrhoeal disease [5]. Consequently, a microbiome that is resilient following an infection is better equipped both to resist a subsequent challenge and impose stronger colonization resistance against invading pathogens such as an antibiotic-resistant bacterial species [4]. The microbiome contributes to health maintenance through colonization resistance against pathogens, physiological conditioning of the gut, and

immune modulation. The role of the microbiota during *C. difficile* infection (CDI) highlights the benefits of a resilient microbiome: recovering early expression pathways analogous to those of a healthy microbiome correlates with enhanced competitive exclusion and host immune response, facilitating pathogen clearance and a return to homeostasis. Conversely, persistent 'infection-associated' expression signatures characterize a microbiome with reduced resilience that continues to allow *C. difficile* persistence, ongoing inflammatory triggering, and disease. These insights have profound implications for understanding gastrointestinal infection and for designing effective microbiota-based therapeutic interventions [4, 5].

Policy Recommendations

The high rate of infections experienced by active duty personnel worldwide and the associated risks of losing personnel and facilities to viral, bacterial, and fungal outbreaks must be considered when preparing resources and protocols. Military commanders have an obligation to mitigate these risks as much as possible. Although the microbiome is a critical factor in infection and resilience [5], its past consideration by the military has been limited to measures taken to intercept infections before they begin [4]. This is partly because studies of resilience in the microbiome have only just started. Optimizing the injury response of the microbiome following infection appears to be a better approach than attempting infection management solely via the traditional science of medicine (such as antibiotic injection). Because the microbiome engrains itself in every facet of human physiology, it is widely sensitive in amplitude to physiological disruption caused by infection (interval I). As a result, the timeeries of the microbiome expresses symptoms that begin only hours after infection (interval II) and can last for weeks (interval III). A policy designed to enable superior prediction of illness using the microbiome is therefore preferable to one designed only to mitigate infection and prevent death. Along with the analysis methods detailed previously, the study of resilience helps to frame the framework for this prediction. Ongoing research will help to define the necessary parameters and criteria for resilience and its oscillations [36-41].

CONCLUSION

Microbiome resilience after infection represents a cornerstone of host recovery and long-term health. Infections disrupt microbial diversity, composition, and function through inflammation, tissue damage, and pathogen competition, often compounded by antibiotics or other therapies. Recovery depends on intrinsic host factors such as genetics and immunity, as well as extrinsic influences including diet, environmental reservoirs, and microbial guilds that facilitate recolonization. While bacterial, viral, and fungal infections each impose distinct disturbances, successful resilience involves the stepwise restoration of microbial diversity, functional pathways, and colonization resistance. Case studies underscore that resilience is neither uniform nor guaranteed, with some microbiomes transitioning to alternative stable states that increase susceptibility to chronic disease or secondary infections. Advances in sequencing, metabolomics, and modeling have deepened insight into resilience mechanisms and identified potential biomarkers to predict recovery trajectories. Interventions such as dietary modulation, probiotics, and fecal microbiota transplantation are emerging as strategies to enhance resilience, though clinical translation requires rigorous validation. At the same time, ethical, privacy, and stewardship challenges must be addressed to ensure responsible microbiome research and data use. Looking forward, longitudinal and integrative studies will be essential to harness microbiome resilience as a therapeutic and preventive tool, bridging infection biology with precision medicine and public health.

REFERENCES

1. Mancin E, Maltecca C, Huang YJ, Mantovani R, Tiezzi F. A first characterization of the microbiota-resilience link in swine. *Microbiome*. 2024 Mar 15;12(1):53.
2. Bucci V, Bradde S, Biroli G, Xavier JB. Social interaction, noise and antibiotic-mediated switches in the intestinal microbiota. *PLoS computational biology*. 2012 Apr 26;8(4):e1002497.
3. Meredith HR, Andreani V, Ma HR, Lopatkin AJ, Lee AJ, Anderson DJ, Batt G, You L. Applying ecological resistance and resilience to dissect bacterial antibiotic responses. *Science advances*. 2018 Dec 5;4(12):eaau1873.
4. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. *Medical Hypotheses*. 2025 Sep 28:111776.
5. Vitko HA, Sekula LK, Schreiber MA. Probiotics for trauma patients: should we be taking a precautionary approach?. *Journal of Trauma Nursing | JTN*. 2017 Jan 1;24(1):46-52.
6. Barrios Steed D, Koundakjian D, Harris AD, Rosato AE, Konstantinidis KT, Woodworth MH. Leveraging strain competition to address antimicrobial resistance with microbiota therapies. *Gut microbes*. 2025 Dec 31;17(1):2488046.

7. Selber-Hnatiw S, Rukundo B, Ahmadi M, Akoubi H, Al-Bizri H, Aliu AF, Ambeaghen TU, Avetisyan L, Bahar I, Baird A, Begum F. Human gut microbiota: toward an ecology of disease. *Frontiers in microbiology*. 2017 Jul 17;8:1265.
8. Fischer MM, Bild M. Gut microbiome composition: back to baseline?. *arXiv preprint arXiv:1906.11546*. 2019 Jun 27.
9. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. *Medical Hypotheses*. 2025 Sep 28;111776.
10. Pham TA, Lawley TD. Emerging insights on intestinal dysbiosis during bacterial infections. *Current opinion in microbiology*. 2014 Feb 1;17:67-74.
11. Melo-González F, Sepúlveda-Alfaro J, Schultz BM, Suazo ID, Boone DL, Kalergis AM, Bueno SM. Distal consequences of mucosal infections in intestinal and lung inflammation. *Frontiers in Immunology*. 2022 Apr 28;13:877533.
12. Shah T, Baloch Z, Shah Z, Cui X, Xia X. The intestinal microbiota: impacts of antibiotics therapy, colonization resistance, and diseases. *International journal of molecular sciences*. 2021 Jun 20;22(12):6597.
13. Arias-Rojas A, Frahm D, Hurwitz R, Brinkmann V, Iatsenko I. Resistance to host antimicrobial peptides mediates resilience of gut commensals during infection and aging in *Drosophila*. *Proceedings of the National Academy of Sciences*. 2023 Sep 5;120(36):e2305649120.
14. Sorensen JW, Shade A. Dormancy dynamics and dispersal contribute to soil microbiome resilience. *Philosophical Transactions of the Royal Society B*. 2020 May 11;375(1798):20190255.
15. Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, Tyler AD, Van Sommeren S, Imhann F, Stempak JM, Huang H. Complex host genetics influence the microbiome in inflammatory bowel disease. *Genome medicine*. 2014 Dec 2;6(12):107.
16. Paul-Chima UO, Ogenyi FC, Ugwu CN, Nnaemeka UM. Gut Microbiota-Derived Metabolites as Early Biomarkers for Childhood Obesity: A Policy Commentary from Urban African Populations. *Obesity Medicine*. 2025 Sep 4;100641.
17. Blekhman R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT, Spector TD, Keinan A, Ley RE, Gevers D, Clark AG. Host genetic variation impacts microbiome composition across human body sites. *Genome biology*. 2015 Sep 15;16(1):191.
18. Singh RK, Chang HW, Yan DI, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, Bhutani T. Influence of diet on the gut microbiome and implications for human health. *Journal of translational medicine*. 2017 Apr 8;15(1):73.
19. An J, Zhao X, Wang Y, Noriega J, Gewirtz AT, Zou J. Western-style diet impedes colonization and clearance of *Citrobacter rodentium*. *PLoS pathogens*. 2021 Apr 5;17(4):e1009497.
20. Jurburg SD, Blowes SA, Shade A, Eisenhauer N, Chase JM. Synthesis of recovery patterns in microbial communities across environments. *Microbiome*. 2024 May 6;12(1):79.
21. David LA, Weil A, Ryan ET, Calderwood SB, Harris JB, Chowdhury F, Begum Y, Qadri F, LaRocque RC, Turnbaugh PJ. Gut microbial succession follows acute secretory diarrhea in humans. *MBio*. 2015 Jul 1;6(3):10-128.
22. Ugwu OP, Okon MB, Alum EU, Ugwu CN, Anyanwu EG, Mariam B, Ogenyi FC, Eze VH, Anyanwu CN, Ezeonwumelu JO, Egba SI. Unveiling the therapeutic potential of the gut microbiota-brain axis: Novel insights and clinical applications in neurological disorders. *Medicine*. 2025 Jul 25;104(30):e43542.
23. The HC, Le SN. Dynamic of the human gut microbiome under infectious diarrhea. *Current Opinion in Microbiology*. 2022 Apr 1;66:79-85.
24. Borgo F, Borghi E, Marzorati S, Iapichino G, Morace G. GUT microbiota change and time of restore in intensive care therapy: a case report. *INTERNATIONAL JOURNAL OF MEDICAL RESEARCH AND HEALTH SCIENCES*. 2016;5(1):110-2.
25. D'humieres C, Delavy M, Alla L, Ichou F, Gauliard E, Ghoulane A, Levenez F, Galleron N, Quinquis B, Pons N, Mullaert J. Perturbation and resilience of the gut microbiome up to 3 months after β -lactams exposure in healthy volunteers suggest an important role of microbial β -lactamases. *Microbiome*. 2024 Mar 12;12(1):50.
26. Edyedu I, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. *Medicine*. 2025 Feb 14;104(7):e41381.

27. Patin NV, Peña-Gonzalez A, Hatt JK, Moe C, Kirby A, Konstantinidis KT. The role of the gut microbiome in resisting norovirus infection as revealed by a human challenge study. *Mbio*. 2020 Dec 22;11(6):10-128.
28. Howe A, Ringus DL, Williams RJ, Choo ZN, Greenwald SM, Owens SM, Coleman ML, Meyer F, Chang EB. Divergent responses of viral and bacterial communities in the gut microbiome to dietary disturbances in mice. *The ISME journal*. 2016 May;10(5):1217-27.
29. Park G, Munley JA, Kelly LS, Kannan KB, Mankowski RT, Sharma A, Upchurch G, Casadesus G, Chakrabarty P, Wallet SM, Maile R. Gut mycobioime dysbiosis after sepsis and trauma. *Critical Care*. 2024 Jan 11;28(1):18.
30. Fukuyama J, Rumker L, Sankaran K, Jeganathan P, Dethlefsen L, Relman DA, Holmes SP. Multidomain analyses of a longitudinal human microbiome intestinal cleanout perturbation experiment. *PLoS computational biology*. 2017 Aug 18;13(8):e1005706.
31. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. *Medicine*. 2025 Jan 17;104(3):e41279.
32. Oliver A, Chase AB, Weihe C, Orchanian SB, Riedel SF, Hendrickson CL, Lay M, Sewall JM, Martiny JB, Whiteson K. High-fiber, whole-food dietary intervention alters the human gut microbiome but not fecal short-chain fatty acids. *Msystems*. 2021 Apr 27;6(2):10-128.
33. Anderson EM, Rozowsky JM, Fazzone BJ, Schmidt EA, Stevens BR, O'Malley KA, Scali ST, Berceli SA. Temporal dynamics of the intestinal microbiome following short-term dietary restriction. *Nutrients*. 2022 Jul 6;14(14):2785.
34. Bolte LA, Vila AV, Imhann F, Collij V, Gacesa R, Peters V, Wijmenga C, Kurilshikov A, Campmans-Kuijpers MJ, Fu J, Dijkstra G. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. *Gut*. 2021 Jul 1;70(7):1287-98.
35. Tan GS, Tay HL, Tan SH, Lee TH, Ng TM, Lye DC. Gut microbiota modulation: implications for infection control and antimicrobial stewardship. *Advances in Therapy*. 2020 Oct;37(10):4054-67.
36. Tan GS, Tay HL, Tan SH, Lee TH, Ng TM, Lye DC. Gut microbiota modulation: implications for infection control and antimicrobial stewardship. *Advances in Therapy*. 2020 Oct;37(10):4054-67.
37. Soni J, Pandey R. Single cell genomics based insights into the impact of cell-type specific microbial internalization on disease severity. *Frontiers in Immunology*. 2024 May 21;15:1401320.
38. Belzer C, Gerber GK, Roeselers G, Delaney M, DuBois A, Liu Q, Belavusava V, Yeliseyev V, Houseman A, Onderdonk A, Cavanaugh C. Dynamics of the microbiota in response to host infection. *PLoS One*. 2014 Jul 11;9(7):e95534.
39. Hawkins AK, O'Doherty KC. "Who owns your poop?": insights regarding the intersection of human microbiome research and the ELSI aspects of biobanking and related studies. *BMC Medical Genomics*. 2011 Oct 7;4(1):72.
40. Charalambous EG, Mériaux SB, Guebels P, Muller CP, Leenen FA, Elwenspoek MM, Thiele I, Hertel J, Turner JD. Early-life adversity leaves its imprint on the oral microbiome for more than 20 years and is associated with long-term immune changes. *International Journal of Molecular Sciences*. 2021 Nov 24;22(23):12682.
41. Li K, Methé BA, Fitch A, Gentry H, Kessinger C, Patel A, Petraglia V, Swamy P, Morris A. Gut and oral microbiota associations with viral mitigation behaviors during the COVID-19 pandemic. *Frontiers in Cellular and Infection Microbiology*. 2022 Sep 9;12:966361.

CITE AS: Wotsomu Evasi (2025). Microbiome Resilience after Infection. IDOSR JOURNAL OF APPLIED SCIENCES 10(3):116-126.
<https://doi.org/10.59298/IDOSRJAS/2025/103.116126>